Scilight Press

Aims

Journal of Neurobiomarkers and Therapeutics (JNBT) is a gold open-access journal and aims to highlight cutting-edge research on the genetic and molecular mechanisms underlying neurological diseases, with a focus on neuromuscular disorders. By integrating insights from genomics, transcriptomics, proteomics, and advanced disease models, we seek to foster a comprehensive understanding of disease progression and identify potential therapeutic targets.

Neuromuscular neurodegenerative disorders encompass a diverse group of conditions that affect the function of motor neurons, muscles, and the nerves controlling them. These disorders, ranging from muscular dystrophies and motor neuron diseases to congenital myopathies and neuromuscular junction disorders, often arise due to genetic mutations and complex molecular mechanisms. Advances in genetics, genomics, and molecular biology have significantly deepened our understanding of disease pathogenesis, paving the way for the development of novel diagnostic and therapeutic strategies. It is published quarterly online by Scilight Press.

Scope

Topics of interest include, but are not limited to:

-Neuro biomarkers for ALS and SMA

-Genetic basis of neuromuscular disorders: Identification and characterization of disease-causing mutations, structural variations, and epigenetic modifications.

-Molecular pathways in disease pathogenesis: Investigation of key signaling pathways, RNA dysregulation, mitochondrial dysfunction, and protein homeostasis in neuromuscular diseases.

-Gene therapy and genome editing: Advances in AAV-mediated gene therapy, antisense oligonucleotides, and RNA-targeted therapies for neuromuscular disorders.

-Translational approaches and targeted therapies: Development of small molecules, biologics, and cell-based therapies for disease modification and symptom management.

-Insights from patient-derived Quality of life, in understanding disease mechanisms and evaluating therapeutic strategies.

-Neuromuscular junction and motor neuron degeneration: Mechanisms underlying synaptic dysfunction, axonal transport defects, and neuroinflammatory responses in disorders such as ALS and SMA.

-Biomarkers and precision medicine: Identification of genetic, transcriptomic, and proteomic biomarkers of Alzheimer's and Parkinson's Disorders for early diagnosis, disease progression monitoring, and personalized treatment strategies.

-Emerging technologies and omics approaches: Applications of MRI and Imaging technology. Spatial reconstruction and multi-omics in unraveling neuromuscular disease and neurodegenerative disease complexity.

Abnormal expression of microRNAs is connected to brain development and neuromuscular diseases and could provide novel biomarkers for the diagnosis and prognosis, and tools for Therapy.

-Challenges in gene therapy applications, clinical trial design, and patient access to emerging therapeutics.